0001144204-10-037808.txt : 20100714 0001144204-10-037808.hdr.sgml : 20100714 20100714130919 ACCESSION NUMBER: 0001144204-10-037808 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100709 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20100714 DATE AS OF CHANGE: 20100714 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMARX THERAPEUTICS INC CENTRAL INDEX KEY: 0001123695 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MOTION PICTURE & VIDEO TAPE PRODUCTION [7812] IRS NUMBER: 860974730 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33043 FILM NUMBER: 10951741 BUSINESS ADDRESS: STREET 1: LEXINGTON AVENUE STREET 2: SUITE 120 CITY: HOLLYWOOD STATE: CA ZIP: 90038 BUSINESS PHONE: (323) 790-1717 MAIL ADDRESS: STREET 1: LEXINGTON AVENUE STREET 2: SUITE 120 CITY: HOLLYWOOD STATE: CA ZIP: 90038 8-K 1 v190598_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 9, 2010
 
IMARX THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
 
         
Delaware
  
001-33043
  
86-0974730
(State or other Jurisdiction of Incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)

     
6860 Lexington Avenue, Suite 120
Los Angeles, CA
  
90038
(Address of Principal Executive Offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (323) 790-1717
 
 
 
(Former name or former address if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 5.07 Submission of Matters to a Vote of Security Holders.
 
On July 9, 2010 ImaRx Therapeutics, Inc. (“ImaRx” or the “Company”) held a Special Meeting of Stockholders.  At the special meeting, the stockholders of ImaRx approved the reincorporation of the Company in the State of Nevada by the following vote:
 
 
Votes For:
  
77,114,506
Votes Against:
  
6000
Abstentions:
  
759
Broker Non-Votes:
  
  0
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  
 
Date:  July 14, 2010
IMARX THERAPEUTICS, INC.
  
       
 
By:
/s/ Edward Sylvan
  
   
Edward Sylvan
  
   
Chief Executive Officer